Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
10
HRTS Quote, Financials, Valuation and Earnings
Last price:
$29.61
Seasonality move
:
12.99%
Day range:
$28.90 - $29.52
52-week range:
$28.81 - $36.03
Dividend yield:
0.49%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
10K
Avg. volume:
16K
1-year change:
0.38%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingTema GLP-1, Obesity & Cardiometabolic ETF has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Tema GLP-1, Obesity & Cardiometabolic ETF has an estimated downside of -- from its current price of $29.15.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -- upside increase from its current price of $29.15.
Fair Value
-
According to the consensus of 0 analysts, Tema GLP-1, Obesity & Cardiometabolic ETF has -- downside to fair value with a price target of -- per share.
HRTS vs. S&P 500
-
Over the past 5 trading days, Tema GLP-1, Obesity & Cardiometabolic ETF has underperformed the S&P 500 by -1.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tema GLP-1, Obesity & Cardiometabolic ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tema GLP-1, Obesity & Cardiometabolic ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tema GLP-1, Obesity & Cardiometabolic ETF reported revenues of --.
Earnings Growth
-
Tema GLP-1, Obesity & Cardiometabolic ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Tema GLP-1, Obesity & Cardiometabolic ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-24 | 2021-12-24 | 2022-12-24 | 2023-12-24 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-24 | 2023-12-24 | 2023-12-24 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HRTS
Sector
Market Cap
--
--
Price % of 52-Week High
--
--
Dividend Yield
0.49%
--
Shareholder Yield
--
--
1-Year Price Total Return
0.38%
--
Beta (5-Year)
--
--
Dividend yield:
0.49%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$30.21
200-day SMA
Sell
Level
$33.08
Bollinger Bands (100)
Sell
Level
31.81 - 34.63
Chaikin Money Flow
Sell
Level
-84.6K
20-day SMA
Sell
Level
$31.42
Relative Strength Index (RSI14)
Sell
Level
27.44
ADX Line
Sell
Level
7.61
Williams %R
Buy
Level
-91.687
50-day SMA
Sell
Level
$32.41
MACD (12, 26)
Sell
Level
-0.80
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-574.1K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, HRTS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRTS average analyst price target in the past 3 months is --.
-
Where Will Tema GLP-1, Obesity & Cardiometabolic ETF Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tema GLP-1, Obesity & Cardiometabolic ETF share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Tema GLP-1, Obesity & Cardiometabolic ETF?
Analysts are divided on their view about Tema GLP-1, Obesity & Cardiometabolic ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tema GLP-1, Obesity & Cardiometabolic ETF is a Sell and believe this share price will rise from its current level to --.
-
What Is Tema GLP-1, Obesity & Cardiometabolic ETF's Price Target?
The price target for Tema GLP-1, Obesity & Cardiometabolic ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HRTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tema GLP-1, Obesity & Cardiometabolic ETF is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HRTS?
You can purchase shares of Tema GLP-1, Obesity & Cardiometabolic ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tema GLP-1, Obesity & Cardiometabolic ETF shares.
-
What Is The Tema GLP-1, Obesity & Cardiometabolic ETF Share Price Today?
Tema GLP-1, Obesity & Cardiometabolic ETF was last trading at $29.61 per share. This represents the most recent stock quote for Tema GLP-1, Obesity & Cardiometabolic ETF. Yesterday, Tema GLP-1, Obesity & Cardiometabolic ETF closed at $29.15 per share.
-
How To Buy Tema GLP-1, Obesity & Cardiometabolic ETF Stock Online?
In order to purchase Tema GLP-1, Obesity & Cardiometabolic ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.33% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.77% over the past day.
